Business Wire

Aktana and Envision Pharma Group Partner to Help Medical Affairs Navigate the Evolving Physician Engagement Landscape

Share

Aktana, the leader in intelligent customer engagement for the life sciences industry, and Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs, announce a strategic partnership that provides medical teams with a comprehensive toolkit for more impactful scientific exchange. By bringing together their extensive technical and industry expertise, Envision and Aktana offer life science companies the ability to enable their medical science liaisons (MSLs) to address HCP demands for personalized, scientifically relevant content and coordinated omnichannel engagement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220927005291/en/

Despite the industry’s separation between commercial and medical teams, today’s HCPs expect MSLs to operate with a holistic view of their engagement with the product. While many life sciences companies have already started equipping commercial teams with technology to synthesize data and coordinate interactions across channels, medical affairs organizations still largely lack the right tools to navigate the dual challenges of information overwhelm and decreasing HCP access.

“MSLs are in a challenging position, learning to balance traditional and modern digital strategies to engage with physicians in an environment where they are asked to respond to questions faster and more frequently,” said Derek Choy, president of Aktana. “With Envision, we can help MSLs by optimizing their HCP engagements to be more relevant, coordinated, and tailored to their individual needs, whether digital or in-person.”

Together, Envision and Aktana will provide medical affairs teams with streamlined, tailored solutions that incorporate Envision’s industry-leading scientific expertise and Aktana’s intelligence platform, which is fueled by a range of integrated data sources and learns from every prior interaction. The partnership arms MSLs with quick, reliable access to the latest scientific information that’s relevant to each HCP, paired with data-driven insights on how, when, and where to deliver that information for optimal customer engagement.

“Like us, Aktana has a long history of helping life sciences companies of all sizes break down data silos, connect internal teams, and generate insights to improve interactions with HCPs,” said Paul Archer, chief commercial officer at Envision. “Together, we will focus on guiding medical affairs teams to build, deploy, and refine their omnichannel strategies so MSLs can deliver value to HCPs when they need it most for improved patient outcomes.”

Archer continued, “We look forward to a long-term partnership with Aktana, as we take the next steps towards our combined vision for a powerful solution that incorporates all touchpoints across the HCP journey.”

In other news today, Aktana announces its hiring of Deepak Patil, senior director of medical strategy.

About Aktana

Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more information, visit www.aktana.com.

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a global, technology-enabled scientific communications company serving pharmaceutical, biotechnology, and medical device companies. As a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility, Envision provides scientific communication services and technology solutions to more than 90 companies, including 19 of the top 20 pharmaceutical companies. Learn more at: www.envisionpharmagroup.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lisa Barbadora
lbarbadora@barbadoraink.com
(610) 420-3413

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AngloGold Ashanti Releases Preliminary Unaudited Condensed Consolidated Financial Statements as of and for the Six Months and the Year Ended 31 December 202319.3.2024 14:04:00 EET | Press release

AngloGold Ashanti plc (“AngloGold Ashanti”, “AGA” or the “Company”) is pleased to provide its preliminary unaudited condensed consolidated financial statements as of and for the six months and the year ended 31 December 2023 (the “FY 2023 Earnings Release”). FY 2023 Financial and Operating Update The FY 2023 Earnings Release should be read together with AngloGold Ashanti’s preliminary financial update for the six months and the year ended 31 December 2023, which was published by the Company on 23 February 2024 (the “FY 2023 Preliminary Financial Update”). No changes have been made in the FY 2023 Earnings Release with respect to the production, cost or cash flow information included in the FY 2023 Preliminary Financial Update. The FY 2023 Preliminary Financial Update combined with the FY 2023 Earnings Release provide the Company’s financial and operating update for the six months and the year ended 31 December 2023. Announcement of Annual General Meeting Date The 2024 Annual General Mee

IFF Announces Sale of its Pharma Solutions Business to Roquette19.3.2024 13:45:00 EET | Press release

IFF (NYSE: IFF) today announced that it has entered into a definitive agreement to sell its Pharma Solutions business unit to French leader of plant-based ingredients Roquette for an enterprise value of up to $2.85 billion, which represents an enterprise value to EBITDA multiple of approximately 13x. IFF’s Pharma Solutions business is a well-established developer and manufacturer of pharmaceutical excipients and includes its Global Specialty Solutions business supporting industrial and methyl cellulosic food applications. The Pharma Solutions business being sold to Roquette is primarily made up of businesses within IFF’s existing Pharma Solutions division, with some adjustments to the perimeter of the transaction designed to align customers, businesses and the manufacturing footprint. “We are pleased to reach an agreement with Roquette that will support Pharma Solutions’ next chapter of growth as a trusted partner for the pharmaceutical industry,” said IFF CEO Erik Fyrwald. "An importa

“Unfortunately, not a lot has changed for girls in football.”19.3.2024 12:00:00 EET | Press release

PUMA CEO Arne Freundt and Alexandra Popp, the captain of the Germany national football team, spoke about leadership and the challenges of women in football. The video interview is part of the sports company’s digital annual report, which was published on March 18 on about.puma.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319731548/en/ Voted Germany’s footballer of the year three times, Alexandra is one of the most prominent ambassadors for women’s football and she is known for her skill and charismatic leadership on the pitch. She started off her career playing in a mixed team, and she distinctly recalled how girls were often belittled and treated unfairly on the pitch. “Football is still pretty tough for girls. The boys in my team were cool. But our opponents were another story. They laughed at you. They said: look, they have a girl in their team, we’ll beat them easily,” Alexandra said. “Or when you play and you

Moove secures USD $100 million Series B round19.3.2024 11:01:00 EET | Press release

Moove, the global mobility fintech that democratises access to vehicle ownership for mobility entrepreneurs, today announces that it has raised $100 million in a Series B funding round, valuing the company at $750m. Uber invested in the round alongside Mubadala, who led Moove’s previous funding round in 2023. The round will enable Moove to expand its customer focused revenue-based vehicle financing offering to 16 markets around the world by the end of 2025. A considerable portion of this expansion will focus on electric vehicles (EVs), which will lay the groundwork for a more sustainable and accessible mobility ecosystem for its customers worldwide. Ladi Delano, Founder of Moove, said: “Today’s announcement marks a significant milestone for us. When we founded Moove in 2020, we were motivated to solve the acute shortage of vehicle financing that over two million African mobility entrepreneurs faced. “This validation from Uber and others stands as a testament to the fact that what was o

Cielo Debuts First Generative AI for Talent Acquisition: CLO.ai19.3.2024 10:11:00 EET | Press release

Cielo, the world’s leading Talent Acquisition Partner, today debuts the first generative AI (GenAI) for talent acquisition: CLO.ai. Based on a new set of industry principles for responsible AI use, the intelligent tool allows talent leaders to maximize the power of GenAI for better hiring outcomes fast, while protecting candidates' experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319387916/en/ “In a competitive, noisy market with many emerging, and sometimes unproven, methodologies and technologies, Cielo has established a responsible approach to artificial intelligence in human resources & talent acquisition. At Cielo, their data scientists, engineers, and talent acquisition experts collaborate to improve GenAI models, assess data for relevancy and accuracy, and operate in a secure environment, thus contributing to an enhanced experience for their clients and candidates. They are not only navigating the landsc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye